


## Anticancer agent 99

Cat. No.:	HY-149061
CAS No.:	2914922-83-9
Molecular Formula:	C <sub>19</sub> H <sub>20</sub> F <sub>3</sub> N <sub>3</sub> O <sub>2</sub>
Molecular Weight:	379.38
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Anticancer agent 99 (compound 2p) has good anticancer activity against HepG2 cells, with an IC <sub>50</sub> value of 35.9 μM. Anticancer agent 99 can induce apoptosis and has anti-proliferation effect <sup>[1]</sup> .								
<b>In Vitro</b>	<p>Anticancer agent 99 (0-50 μM, 24 h) directly upregulates Bax expression and induces caspase-3-dependent apoptosis in HepG2 cell line, with antiproliferative effects<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 cell</td> </tr> <tr> <td>Concentration:</td> <td>25, 50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td> <p>Increased mRNA transcript levels of pro-apoptotic Bax and Caspase-3 genes.</p> <p>Reduced Akt protein levels in HepG2 cells.</p> <p>Increased FoXO1, TXNIP and p27 protein levels in HepG2 cells.</p> </td> </tr> </table>	Cell Line:	HepG2 cell	Concentration:	25, 50 μM	Incubation Time:	24 h	Result:	<p>Increased mRNA transcript levels of pro-apoptotic Bax and Caspase-3 genes.</p> <p>Reduced Akt protein levels in HepG2 cells.</p> <p>Increased FoXO1, TXNIP and p27 protein levels in HepG2 cells.</p>
Cell Line:	HepG2 cell								
Concentration:	25, 50 μM								
Incubation Time:	24 h								
Result:	<p>Increased mRNA transcript levels of pro-apoptotic Bax and Caspase-3 genes.</p> <p>Reduced Akt protein levels in HepG2 cells.</p> <p>Increased FoXO1, TXNIP and p27 protein levels in HepG2 cells.</p>								

### REFERENCES

[1]. M İhsan Han, et al. Design, Synthesis, and Anticancer Evaluation of Novel Tetracaine Hydrazide-Hydrazones. ACS Omega. 2023 Feb 28;8(10):9198-9211.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA